secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001737287-25-000063
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Q1 net loss $59.7M; ALPHA3 milestone delayed to 1H 2026; cash runway to 2H 2027
--------------------------------------------------------------------------------

- Net loss $59.7M ($0.28/sh); R&D $50.2M, G&A $15M; cash, equivalents & investments $335.5M.
- ALPHA3 (cema-cel) lymphodepletion/futility analysis shifted to 1H 2026; >250 patients consented, ~50 sites activated.
- ALLO-329 RESOLUTION basket trial in AID starts mid-2025; proof-of-concept data moved to 1H 2026.
- ALLO-316 TRAVERSE updated Phase 1b results to be presented at ASCO June 1, 2025.
- Cash runway extended into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP op ex ~$230M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728725000063/0001737287-25-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728725000063/allo-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001737287-25-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer